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Abstract 15 
Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide. This 16 
study determined the minimum inhibitory concentrations of closthioamide to be 0.008-0.5 mg/L 17 
for clinical N. gonorrhoeae strains and related species. Cross-resistance with existing 18 
antimicrobial resistance was not detected, indicating that closthioamide could be used to treat 19 
drug-resistant N. gonorrhoeae.  20 
 21 
 22 
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TEXT 24 
Neisseria gonorrhoeae is one of the most important antimicrobial resistance (AMR) threats 25 
worldwide(1). Since the discovery of penicillin N. gonorrhoeae has developed resistance to every 26 
therapeutic antimicrobial agent used(2).  27 
Dual therapy for gonorrhoea, with ceftriaxone and azithromycin, was introduced in 2011(3) as a 28 
strategy to delay AMR. These antibiotics represent the last reliable classes of antibiotics 29 
recommended for empirical treatment of N. gonorrhoeae infection(4) and worryingly, the 30 
minimum inhibitory concentrations (MIC) to both antibiotics are increasing annually(5). This is 31 
complicated further by reports of treatment failure due to extended spectrum cephalosporin 32 
(ESC) resistance occurring worldwide.  33 
In 2012, the World Health Organisation (WHO) published an action plan to combat the spread 34 
and impact of N. gonorrhoeae(1). Given that there is no effective vaccine against gonorrhoea 35 
and antimicrobial therapy is still one the most important means of gonorrhoea control, the WHO 36 
advocates research into new antimicrobials(1). 37 
Closthioamide (CTA), discovered in 2010, was isolated from the anaerobic bacterium Clostridium 38 
cellulolyticum(6). It represents a new class of natural polythioamide antibiotics and has been 39 
shown to have high in vitro activity against other AMR microorganisms(7). Its mode of action is 40 
thought to be inhibition of DNA gyrase(7). Cross-resistance to quinolone antibiotics has not been 41 
observed to-date, suggesting a different mechanism of action(7). Given its high potency with 42 
multi-drug resistant (MDR) bacteria, closthioamide is a candidate antibiotic to test against N. 43 
gonorrhoeae. 44 
 45 
Bacterial strains and antimicrobial susceptibility testing. A total of 149 clinical and eight 46 
WHO reference N. gonorrhoeae isolates as well as four commensal Neisseria strains were 47 
examined in this study.  These were provided by Barts Health NHS Trust, St George’s University 48 
Hospitals NHS Foundation Trust, Royal Free NHS Foundation Trust and Tunbridge Wells NHS 49 
Trust hospital laboratories. The MICs for CTA were determined by the agar dilution method as 50 
previously described(8). The CTA MIC range tested was 0.002 mg/L - 1 mg/L. Of the 149 clinical 51 
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strains, 131 had previously determined MICs to penicillin, ceftriaxone, azithromycin, 52 
ciprofloxacin, tetracycline and spectinomycin and 127 had known MICs to cefixime.  53 
CTA synthesis. Closthioamide was synthesized according to the route of Hertweck and 54 
coworkers(9, 10). The core of CTA was synthesized by two consecutive peptide couplings and 55 
deprotections onto a 1,3-diaminopropane core with an N-protected beta-alanine, followed by a 56 
third peptide coupling to install the aromatic benzoic acid end caps. Thionation with Lawesson’s 57 
reagent and deprotection under highly acidic conditions yielded CTA in five longest linear steps.  58 
All reagents involved in the synthesis of CTA were obtained from Sigma-Aldrich, with the 59 
exception of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) from Manchester Organics. 60 
All reaction solvents used in synthesis were anhydrous and of the highest grade from Sigma-61 
Aldrich. All routine solvents for workup and purification were obtained from VWR. Closthioamide 62 
stock solution was prepared at 100 mg/L in 100% ethanol. 63 
Statistical analysis. MIC50 and MIC90 were calculated with MIC data from clinical gonococcal 64 
strains only. The correlation between CTA MICs and those for other antibiotics was determined 65 
with a Spearman’s Rank correlation test, using STATA 14.2. The correlation coefficient was 66 
calculated using MIC data from clinical and reference gonococcal strains. 67 
 68 
CTA susceptibility and cross-resistance to existing antimicrobials. The CTA MIC range of 69 
the 149 clinical strains was between 0.008 mg/L – 0.25 µmg/L. The number of isolates with MICs 70 
of 0.008 mg/L, 0.015 µmg/L, 0.031 µmg/L, 0.063 mg/L, 0.125 mg/L and 0.25 mg/L were one 71 
(1%), six (4%), 14 (9%), 53 (36%), 72 (48%) and three (2%) respectively (Figure 1). The MIC50 72 
and MIC90 were 0.063 mg/L and 0.125 mg/L respectively. The CTA MICs of N. lactamica and N. 73 
perflava were 0.063 mg/L and 0.5 mg/L respectively and both N. flavescens strains had an MIC 74 
of >1 mg/L.  75 
No significant correlation was identified between the tested antibiotics; ciprofloxacin, a 76 
fluoroquinolone, had a correlation coefficient of 0.07 (Figure 2, Table 2), the highest correlation 77 
was 0.48 with azithromycin.  78 
 79 
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The imminent threat of untreatable gonorrhoea is a global problem that urgently requires the 80 
development of new antimicrobial agents. In this study, the novel antimicrobial CTA inhibited the 81 
growth of 146/149 (98%) of clinical gonococcal strains at ≤0.125mg/L, suggesting a low 82 
therapeutic dose concentration which would reduce any potential toxicity. Importantly isolates 83 
resistant to ciprofloxacin and the first line therapeutic agents ceftriaxone and azithromycin are as 84 
susceptible to CTA as strains sensitive to these antibiotics, suggesting CTA could be effective 85 
clinically against MDR N. gonorrhoeae strains. Closthioamide activity against N. gonorrhoeae is 86 
comparable to its activity against other AMR organisms(7).  87 
The CTA mode of action has been linked to DNA gyrase, which is also a target for 88 
fluoroquinolones suggesting the potential for cross-resistance with antibiotics such as 89 
ciprofloxacin. However, analysis of the clinical isolates demonstrated no correlation between 90 
MICs of the two antibiotics. This is also supported by a study by Chiriac et al who found no cross-91 
resistances between the two antimicrobials, although they did not examine N. gonorrhoeae(7). 92 
This suggests that the active site for CTA may be elsewhere in the quinolone resistance 93 
determining region (QRDR). 94 
Interestingly, the two N. perflava strains had the highest CTA MIC (>1 mg/L) and the basis of this 95 
relative resistance requires further research to understanding the specific resistance 96 
mechanisms.  97 
In conclusion, CTA has high anti-gonococcal activity in vitro, even for multidrug resistant isolates, 98 
but further studies to evaluate the clinical potential of this antimicrobial are urgently required in 99 
light of the public health threat that gonorrhoea poses. 100 
 101 
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TABLES AND FIGURES LEGENDS  152 
 153 
Figure 1. Susceptibility of gonococcal isolates to closthioamide (CTA).  154 
CTA was tested on 149 clinical gonococcal strains (range tested was 0.002mg/L – 1 mg/L).  155 
 156 
 157 
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Table 1. MICs of WHO gonococcal reference strains. Minimum inhibition concentration (MICs) 158 
(mg/L) determined by World Health Organisation (WHO) for penicillin (PEN), cefixime (CFX), 159 
ceftriaxone (CRO), azithromycin (AZI), ciprofloxacin (CIP), tetracycline (TET), spectinomycin 160 
(SPE). Closthioamide (CTA) MIC was determined by agar dilution in this study.  161 
 162 
 163 
Figure 2. Correlation between CTA and ciprofloxacin MICs. MIC data for CTA and 164 
ciprofloxacin from 139 clinical strains was used to calculate a correlation coefficient (R
2
) of 0.07. 165 
 166 
 167 
Table 2. Raw data showing number of clinical isolates with given combination of CTA and 168 
Ciprofloxacin MICs.  169 
 170 
 171 
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Table 1. MICs of WHO gonococcal reference strains. Minimum inhibition concentration (MICs) 
(mg/L) determined by World Health Organisation (WHO) for penicillin (PEN), cefixime (CFX), 
ceftriaxone (CRO), azithromycin (AZI), ciprofloxacin (CIP), tetracycline (TET), spectinomycin 
(SPE). Closthioamide (CTA) MIC was determined by agar dilution in this study.  
 
 
 
WH
O 
N
. g
on
o
rr
ho
ea
e S
tra
ins
  Antibiotics tested
 PEN CFX CRO AZI CIP TET SPE CTA 
WHO F 0.032 <0.016 <0.002 0.125 0.004 0.25 32 0.063 
WHO G 0.5 <0.16 0.008 0.25 0.125 32 16 0.063 
WHO K  2 0.5 0.064 0.25 >32 2 16 0.5 
WHO L 2 0.25 0.125 0.5 >32 4 16 0.125 
WHO M 8 <0.016 0.012 0.25 2 1 16 0.125 
WHO N 8 <0.016 0.004 0.125 4 16 16 0.125 
WHO O >32 0.016 0.032 0.25 0.008 1 >1024 0.063 
WHO P 0.25 <0.016 0.004 2 0.004 0.5 16 0.125 
 MIC 
breakpoint 
2 0.25 0.25 2 1 2 128 n/a 
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Table 2. Raw data showing number of clinical isolates with given combination of CTA and 
Ciprofloxacin MICs.  
 
Cip
rof
lox
ac
in 
MI
Cs
 (m
g/L
) 
CTA MICs (mg/L) 
0.008 0.015 0.031 0.063 0.125 0.25 0.5 Total
0.002 0 0 2 1 3 1 0 7 
0.003 0 0 1 6 8 0 0 15 
0.004 0 1 1 10 6 0 0 18 
0.006 0 2 3 7 6 1 0 19 
0.008 0 0 3 6 14 0 0 23 
0.012 0 0 1 1 4 0 0 6 
0.016 0 0 1 5 1 0 0 7 
0.023 0 0 0 1 3 0 0 4 
0.04 0 0 0 0 1 0 0 1
0.064 0 0 0 0 1 0 0 1 
0.094 0 0 0 0 1 0 0 1 
0.125 0 0 0 1 0 0 0 1 
0.25 0 1 0 0 0 0 0 1 
1 0 0 1 0 0 0 0 1 
1.5 0 0 0 1 0 0 0 1 
2 0 0 1 0 2 0 0 3 
3 0 0 0 1 3 0 0 4 
4 1 1 0 2 1 0 0 5
6 0 0 0 0 2 0 0 2 
8 0 0 0 3 0 0 0 3 
12 0 0 0 1 0 0 0 1 
16 0 0 0 1 2 0 0 3 
32 0 0 0 4 6 1 1 12 
Total 1 5 14 51 64 3 1 139 
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